AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.700
-0.060 (-1.60%)
At close: Apr 9, 2026, 4:00 PM EDT
3.750
+0.050 (1.35%)
After-hours: Apr 9, 2026, 6:42 PM EDT
AtaiBeckley Revenue
In the year 2025, AtaiBeckley had annual revenue of $4.09M with 1,227.60% growth. AtaiBeckley had revenue of $1.07M in the quarter ending December 31, 2025.
Revenue (ttm)
$4.09M
Revenue Growth
+1,227.60%
P/S Ratio
330.05
Revenue / Employee
$41,303
Employees
99
Market Cap
1.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.09M | 3.78M | 1,227.60% |
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| Iovance Biotherapeutics | 263.50M |
| Monte Rosa Therapeutics | 123.67M |
| Immatics | 56.67M |
| Wave Life Sciences | 42.73M |
| Taysha Gene Therapies | 9.77M |
| Maze Therapeutics | 2.50M |
ATAI News
- 1 day ago - AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response - Benzinga
- 1 day ago - AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - GlobeNewsWire
- 16 days ago - AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst - GlobeNewsWire
- 4 weeks ago - BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - GlobeNewsWire
- 4 weeks ago - AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - GlobeNewsWire
- 6 weeks ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 6 weeks ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 6 weeks ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire